R&D Services and Training
Translational R&D and Capacity Building
01 May 2017 to 30 April 2022
European Vaccine Initiative
10.6 Mio Euro
Vaccines are one of the most successful and cost-effective public health tools. However, their development is time-consuming and complex, requiring a combination of specialised skills and technical capacities not readily available at a single organisation. TRANSVAC2, a European vaccine research and development (R&D) infrastructure, facilitates access to these skills and capacities, and promotes collaborations in the European vaccine landscape - aiming thereby to accelerate the development of safe, effective and affordable vaccines by:
providing high quality technical services across four platforms: Technology, Immunocorrelates & Systems Biology, Animal models, and Support for Clinical Trials. Academic and non-academic research groups can apply to benefit from the expertise and facilities offered by TRANSVAC2 partners.
addressing current gaps in vaccine development and developing cutting-edge technologies to address it, thereby increasing the quality of services provided.
offering training that provides fundamental and advanced knowledge on vaccine development-related topics. TRANVAC2 centralises and expands training opportunities available to the European vaccine community.
TRANSVAC2´s comprehensive approach catalyses optimization, sustainability and harmonization of the vaccine development workflow by driving Europe’s capacity in vaccinology and contributes to the development of effective products to address European and global health challenges.
Vaccine R&D Pipeline